Ageing and prior infection with cytomegalovirus (CMV) produce well-described alterations in T-cell immunity. Age is also a risk factor for many cancers, including melanoma, for which systemic therapies such as immune checkpoint blockade (ICB) that modify T-cell function are commonly used. How age-related and CMV-driven immune changes interact with ICB-induced immune modulation and with clinical outcomes remains unclear. The authors sought to clarify whether age or CMV serostatus are associated with baseline immune phenotype, early treatment-induced immune changes, or clinical outcome in patients receiving ICB for advanced melanoma.
The analysis comprised 79 patients with advanced melanoma whose peripheral blood was sampled for flow cytometric evaluation before and early during ICB. The cohort included older patients defined as those aged ≥65 years. Treatment regimens included PD-1 and CTLA-4 checkpoint inhibitors, and some patients received PD-1 with or without LAG-3 blockade. The investigators compared cellular phenotypes, cytokine and inhibitory marker expression, and early on-treatment immune changes across strata defined by age and CMV serostatus, and related these findings to clinical outcomes.
At baseline, older patients (≥65 years) exhibited specific differences in circulating lymphocyte subsets compared with younger patients. Older age was associated with fewer CD8+ Tnaive cells, fewer CD4+ central memory (Tcm) cells, reduced T follicular helper (TFH) populations, and lower B cell counts. Conversely, older patients had increased frequencies of CD8+ TemRA cells. Despite these compositional differences, cytokine production profiles and expression of inhibitory markers were reported as similar between older and younger patients prior to treatment.
CMV seropositivity was linked to a different pattern of immune alteration at baseline. CMV-positive patients showed expansion of both CD8+ and CD4+ TemRA populations with evidence of enhanced effector function. Notably, CMV-driven expansions did not coincide with reductions in naive T-cell pools, distinguishing the CMV-associated phenotype from the age-associated phenotype. Thus, age and CMV each associated with significant but largely distinct alterations in T-cell phenotype before ICB.
After a single cycle of ICB, the investigators observed immune cell expansion and phenotype changes in peripheral blood. The magnitude and some qualitative aspects of these early on-treatment changes differed between regimens: effects following combined PD-1 and CTLA-4 blockade were of greater magnitude and partially distinct from those seen with PD-1 with or without LAG-3 blockade. Importantly, these treatment-induced immune alterations were reported to be largely independent of patient age and CMV serostatus, indicating a broadly similar early immune response to ICB across those subgroups within this cohort.
Across the cohort, neither chronological age nor CMV serostatus was associated with differences in clinical outcomes following ICB. Despite measurable baseline differences in T-cell subset distributions related to age and to CMV, these factors did not predict the measured clinical or immunological response to immune checkpoint therapies in the studied advanced melanoma patients.
This work is reported as a medRxiv preprint and has not been certified by peer review; the authors note that the findings should not be used to guide clinical practice without further validation. Ethical approval for the study was provided by the Alfred Ethics Committee of The Alfred Hospital (535/19 and 507/20) and the Monash University Human Research Ethics Committee (26385). The manuscript states that the study data are available upon request from the corresponding authors. Funding sources declared include the Victorian Cancer Agency (CRF15004) and the National Health and Medical Research Council (GNT1090906l, GNT2034195).
In this cohort of 79 advanced melanoma patients, ageing and CMV seropositivity each associated with distinct baseline alterations in T-cell phenotype, but neither factor altered cytokine or inhibitory marker expression pre-treatment nor influenced early treatment-induced immune changes or clinical outcome following ICB. The study concludes that, within the limits of this dataset, age and CMV are not associated with differential clinical or immunological response to immune checkpoint blockade.